KUR.F · Kura Oncology, Inc

-

Please sign in to comment on KUR.F

1 Comment

Admin

4 years, 11 months ago

Kura Oncology, Inc is currently in a long term downtrend where the price is trading 33.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Kura Oncology, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 46.4% to $-26M since the same quarter in the previous year.

Finally, its free cash flow fell by 33.4% to $-19M since the same quarter in the previous year.

Based on the above factors, Kura Oncology, Inc gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	US50127T1097
Sector	Healthcare
Industry	Biotechnology

Dividend Yield	None
PE Ratio	None
Target Price	44.57
Beta	0.22

ABOUT

Kura Oncology, Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

KUR.F · Kura Oncology, Inc

-

Kura Oncology, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Kura Oncology, Inc using a moving average strategy